Our Hypermatrix™ technologies are central to the development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Hypermatrix™ technologies are a multidimensional controlled-release drug delivery platform that we believe can be applied to the efficient development of a wide range of existing and new pharmaceuticals. We believe that the flexibility of these technologies allows us to develop complex drug delivery solutions within an industry-competitive timeframe. Based on this technology platform, we have developed several drug delivery systems and a pipeline of products (some of which have received final FDA approval) and product candidates in various stages of development, including ANDAs filed with the FDA and one NDA filing.

The technology that is central to our abuse deterrent formulation of Oxycodone hydrochloride ER is the novel Point of Divergence Drug Delivery System ("nPODDDS™"). nPODDDS™ is designed to provide for certain unique drug delivery features in a product. Our PODRAS™ delivery technology platform was designed to prevent overdose when more pills than prescribed are swallowed intact

The flexibility of our technologies allows us to quickly develop complex drug delivery solutions and focus our development activities in three niche markets:

• Improved current therapies through controlled-release (NDA regulatory path)
• Abuse deterrence
• Difficult-to-produce controlled-release generic drugs (ANDA regulatory path)